ImmunoGen in the News
WALTHAM, Mass.--(BUSINESS WIRE) --Jul. 31, 2023-- ImmunoGen (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2023.
From ImmunoGen
Mark Enyedy, ImmunoGen’s President and Chief Executive Officer said, “This quarter we achieved a . . .